 | An editor has performed a search and found that
sufficient sources exist to establish the subject's
notability. (January 2024) |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AMG757; AMG-757 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Tarlatamab is a bispecific T cell engager that binds DLL3 and CD3 which has shown promise for previously treated small cell lung cancer. [1]
References
- ^ Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. (November 2023). "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer". The New England Journal of Medicine. 389 (22): 2063–2075. doi: 10.1056/NEJMoa2307980. PMID 37861218.
 | This medical article is a stub. You can help Wikipedia by expanding it. |